NO932148L - Fusjonspolypeptider - Google Patents

Fusjonspolypeptider

Info

Publication number
NO932148L
NO932148L NO93932148A NO932148A NO932148L NO 932148 L NO932148 L NO 932148L NO 93932148 A NO93932148 A NO 93932148A NO 932148 A NO932148 A NO 932148A NO 932148 L NO932148 L NO 932148L
Authority
NO
Norway
Prior art keywords
dpp
fusion polypeptides
fusion protein
extension
proteins
Prior art date
Application number
NO93932148A
Other languages
English (en)
Other versions
NO932148D0 (no
Inventor
Teresa M Kubiak
Satish K Sharma
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of NO932148D0 publication Critical patent/NO932148D0/no
Publication of NO932148L publication Critical patent/NO932148L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57536—Endothelin, vasoactive intestinal contractor [VIC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Et ikke-naturlig forekommende fusjonsprotein omfattende en forlengelsespeptiddel kovalent kjedet ved dens C-ende til N-enden av en biologisk aktiv del, er beskrevet. Forlengelses- peptiddelen kan fjernes ved DPP IV- spaltning. Anvendelse av fusjonspro- teiner med DPP IV-spaltbare forlengel- sespeptiddeler i medisinske preparater er beskrevet. En metode for rensing av ønskede proteiner fra en blanding inneholdende et fusjonsprotein, er be- skrevet.
NO93932148A 1990-12-13 1993-06-11 Fusjonspolypeptider NO932148L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62672790A 1990-12-13 1990-12-13
PCT/US1991/009152 WO1992010576A1 (en) 1990-12-13 1991-12-12 Fusion polypeptides

Publications (2)

Publication Number Publication Date
NO932148D0 NO932148D0 (no) 1993-06-11
NO932148L true NO932148L (no) 1993-08-09

Family

ID=24511577

Family Applications (1)

Application Number Title Priority Date Filing Date
NO93932148A NO932148L (no) 1990-12-13 1993-06-11 Fusjonspolypeptider

Country Status (13)

Country Link
EP (1) EP0561971A1 (no)
JP (1) JPH06503473A (no)
AU (1) AU662508B2 (no)
CA (1) CA2094512A1 (no)
CZ (1) CZ109393A3 (no)
FI (1) FI932680L (no)
HU (1) HUT69963A (no)
IE (1) IE914347A1 (no)
NO (1) NO932148L (no)
RU (1) RU2114119C1 (no)
SK (1) SK60893A3 (no)
TW (1) TW213923B (no)
WO (1) WO1992010576A1 (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9906715D0 (en) * 1999-03-23 1999-05-19 Ferring Bv Compositions for promoting growth
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
US6759393B1 (en) 1999-04-12 2004-07-06 Pfizer Inc. Growth hormone and growth hormone releasing hormone compositions
CA2303702A1 (en) * 1999-04-12 2000-10-12 Pfizer Products Inc. Growth hormone and growth hormone releasing hormone compositions
JP2003514532A (ja) * 1999-11-19 2003-04-22 トランスカーヨティック セラピーズ インコーポレイテッド 生成物の産生量を最適化するための核酸構築体
GB0010188D0 (en) * 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
EP1205551A1 (en) * 2000-11-09 2002-05-15 Pfizer Products Inc. Growth hormone and growth hormone releasing hormone compositions
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
PT1454138E (pt) * 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
GB2389115B (en) * 2001-12-14 2005-03-16 Asterion Ltd Polypeptide having a plurality of modified growth hormone receptor binding domains of growth hormone
ATE498404T1 (de) 2003-12-09 2011-03-15 Novo Nordisk As Regulierung der nahrungspräferenz mit glp-1- agonisten
JP2008501765A (ja) 2004-06-11 2008-01-24 ノボ　ノルディスク　アクティーゼルスカブ Ｇｌｐ−１アゴニストを用いた薬剤誘発性肥満の中和
BRPI0606992A2 (pt) 2005-02-11 2009-07-28 Amylin Pharmaceuticals Inc análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP1996937A4 (en) † 2006-03-06 2009-04-08 Amunix Inc GENETIC PACKS AND USES THEREOF
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
CA2748314C (en) 2009-02-03 2018-10-02 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
AU2010290131C1 (en) 2009-08-24 2015-12-03 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
US9447150B2 (en) 2010-01-29 2016-09-20 Iowa State University Research Foundation, Inc. Peptide domains that bind small molecules of industrial significance
CA2864126A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
BR112014020694A2 (pt) 2012-02-15 2018-05-08 Amunix Operating Inc. proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
IL319473A (en) 2016-12-02 2025-05-01 Bioverativ Therapeutics Inc Methods for treating hemophilic arthritis using chimeric blood clotting factors
CA3067674A1 (en) * 2017-06-29 2019-01-03 Ureka Sarl Pro-drug peptide with improved pharmaceutical properties
BR112020022164A2 (pt) 2018-05-18 2021-02-02 Bioverativ Therapeutics Inc. métodos de tratamento de hemofilia a

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703004A (en) * 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4569794A (en) * 1984-12-05 1986-02-11 Eli Lilly And Company Process for purifying proteins and compounds useful in such process
US4734399A (en) * 1985-08-06 1988-03-29 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
CA1340522C (en) * 1987-03-10 1999-05-04 Heinz Dobeli Fusion proteins containing neighbouring histidines for improved purification
CA2057895A1 (en) * 1989-06-16 1990-12-17 Teresa M. Kubiak Stabilized, potent grf analogs
JP3346563B2 (ja) * 1990-04-09 2002-11-18 ファルマシア・アンド・アップジョン・カンパニー 組換え蛋白類を精製する改良方法および該方法で有用な化合物類

Also Published As

Publication number Publication date
JPH06503473A (ja) 1994-04-21
WO1992010576A1 (en) 1992-06-25
FI932680A7 (fi) 1993-06-11
AU662508B2 (en) 1995-09-07
FI932680A0 (fi) 1993-06-11
TW213923B (no) 1993-10-01
RU2114119C1 (ru) 1998-06-27
FI932680L (fi) 1993-06-11
EP0561971A1 (en) 1993-09-29
IE914347A1 (en) 1992-06-17
HUT69963A (en) 1995-09-28
CZ109393A3 (en) 1994-01-19
AU9116591A (en) 1992-07-08
CA2094512A1 (en) 1992-06-14
NO932148D0 (no) 1993-06-11
SK60893A3 (en) 1993-10-06
HU9301705D0 (en) 1993-10-28

Similar Documents

Publication Publication Date Title
NO932148L (no) Fusjonspolypeptider
Bedarkar et al. Relaxin has conformational homology with insulin
Matsuo et al. Synthesis of the porcine LH-and FSH-releasing hormone by the solid-phase method
CA1223198A (en) Repair of tissue in animals
RU93045577A (ru) Слитные полипептиды
BG60256B1 (bg) Рекомбинантен метод за получаване на лимфотоксин
NO178789B (no) Fremgangsmåte for fremstilling av gamma-interferonpolypeptid med forbedret stabilitet, ekspresjonsvektor samt DNA-sekvens kodende for polypeptidene
NZ504752A (en) Hydrophobically-modified protein compositions (particularly hedgehog proteins)
JPS6410999A (en) Production of physiologically active peptide containing cysteine residue
DK149092C (da) Analogifremgangsmaade til fremstilling af tripeptider eller farmaceutisk acceptable syreadditionssalte deraf
Schwartz et al. A highly potent insulin: des-(B26-B30)-[AspB10, TyrB25-NH2] insulin (human).
JPS6420095A (en) Polypeptide having anti-blood coagulating action
Meloun et al. Amino acid sequence of bovine spleen cathepsin B.
DK162130B (da) Grf-analoge peptider, fremgangsmaade til fremstilling deraf, grf-analoge peptider som terapeutiske midler, anvendelse af grf-analoge peptider, fremgangsmaade til fremstilling af farmaceutiske praeparater indeholdende grf-analoge peptider samt parenterale farmaceutiske praeparater indeholdende grf-analoge peptider
Heath et al. (ACB) human proinsulin, a novel insulin agonist and intermediate in the synthesis of biosynthetic human insulin.
Burke et al. Superactive insulins
FR2408580A1 (fr) Compositions de polypeptides contenant la sequence l-arginine-l-lysine-(acide l-aspartique)-l-valine-l-tyrosine, leur procede d'obtention et compositions therapeutiques en comportant
Lai et al. Primary structure of cholera toxin B-subunit
KR890014735A (ko) 변형 단백질
YU64192A (sh) Analozi insulina
AU6393990A (en) Hiv related peptides
Massey et al. Guinea pig proinsulin. Primary structure of the C-peptide isolated from pancreas
YAMASHIRO et al. β‐Endorphin: Synthesis and properties of double‐headed and related analogs
US4330465A (en) Novel β-endorphin analogs
Balasubramaniam et al. Synthesis of sequences 1–16 and 63–95 of Cerebratulus lacteus toxin AIII: Hemolytic activity in a toxin fragment